TLC Reports Second Quarter 2020 Financial Results and Provides Business Update
05 août 2020 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 05, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19
15 juil. 2020 07h23 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan , July 15, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces Completion of US$23 Million Financing
30 juin 2020 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 30, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy
31 mai 2020 00h09 HE
|
TLC
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage
18 mai 2020 02h52 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 18, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Reports First Quarter 2020 Financial Results and Provides Business Update
13 mai 2020 04h12 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 13, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a Row
04 mai 2020 05h47 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 04, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy
12 févr. 2020 04h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Reports Fiscal Year End 2019 Financial Results and Provides Business Update
11 févr. 2020 05h45 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy
08 janv. 2020 04h00 HE
|
TLC
Part 2 will dose ~150 patients with TLC590, bupivacaine, or placeboPrimary endpoint: AUC0-72 on numerical pain rating scaleEnrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA...